5472fa65-a8e2-4593-abd8-e241d1bdec84
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
- age_years
- 72.0903490759754
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- PROTEIN_SECRETION+0.400
- TGF_BETA_SIGNALING+0.370
- UV_RESPONSE_DN+0.370
- ANDROGEN_RESPONSE+0.350
- ANGIOGENESIS+0.340
- G2M_CHECKPOINT+0.340
- EPITHELIAL_MESENCHYMAL_TRANSITION+0.300
- NOTCH_SIGNALING+0.290
- MITOTIC_SPINDLE+0.240
- SPERMATOGENESIS+0.230
Top 10 suppressed
- DNA_REPAIR-0.210
- KRAS_SIGNALING_DN-0.200
- XENOBIOTIC_METABOLISM-0.180
- INTERFERON_ALPHA_RESPONSE-0.150
- TNFA_SIGNALING_VIA_NFKB-0.130
- APICAL_SURFACE-0.120
- INTERFERON_GAMMA_RESPONSE-0.120
- CHOLESTEROL_HOMEOSTASIS-0.100
- ALLOGRAFT_REJECTION-0.090
- MYC_TARGETS_V2-0.090
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | MNG56 | — | — | 0.833 |
| 2 | TCGA-96-7544-01A-11R-2045-07 | — | cohortSQ1 | 0.777 |
| 3 | TCGA-E9-A226-01A-21R-A157-07 | — | B | 0.768 |
| 4 | TCGA-44-8119-01A-11R-2241-07 | — | cohortA3 | 0.746 |
| 5 | SRR23303749 | — | — | 0.730 |
| 6 | TCGA-AR-A24L-01A-11R-A169-07 | — | B | 0.730 |
| 7 | SRR25617891 | — | E | 0.722 |
| 8 | TCGA-BH-A1FM-01A-11R-A13Q-07 | — | B | 0.720 |
| 9 | MBCProject_5953_T1_RNA | — | B | 0.712 |
| 10 | TCGA-55-6975-01A-11R-1949-07 | — | cohortA4 | 0.710 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 31 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| PROTEIN_SECRETION | 0.400 | Remibrutinib | — uncovered |
| TGF_BETA_SIGNALING | 0.370 | Inavolisib | — uncovered |
| UV_RESPONSE_DN | 0.370 | Inavolisib | — uncovered |
| ANDROGEN_RESPONSE | 0.350 | Inavolisib | — uncovered |
| ANGIOGENESIS | 0.340 | Remibrutinib | — uncovered |
| G2M_CHECKPOINT | 0.340 | Inavolisib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.300 | Inavolisib | — uncovered |
| NOTCH_SIGNALING | 0.290 | Inavolisib | — uncovered |
| MITOTIC_SPINDLE | 0.240 | Inavolisib | — uncovered |
| SPERMATOGENESIS | 0.230 | Inavolisib | — uncovered |
| MTORC1_SIGNALING | 0.220 | Inavolisib | — uncovered |
| E2F_TARGETS | 0.190 | Inavolisib | — uncovered |
| PI3K_AKT_MTOR_SIGNALING | 0.150 | Inavolisib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.140 | Idelalisib | — uncovered |
| HEDGEHOG_SIGNALING | 0.130 | Inavolisib | — uncovered |
| MYC_TARGETS_V1 | 0.130 | Inavolisib | — uncovered |
| KRAS_SIGNALING_UP | 0.100 | Inavolisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.080 | Inavolisib | — uncovered |
| APICAL_JUNCTION | 0.070 | Inavolisib | — uncovered |
| IL2_STAT5_SIGNALING | 0.070 | Idelalisib | — uncovered |